Future oncology最新文献_第3页

User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol. 以用户为中心的癌症患者COPD护理路径设计：混合方法临床试验方案

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-14 DOI: 10.1080/14796694.2025.2562715

T W Lycan, S N Price, K Mileham, E Stoen, J Ruiz, J A Ohar, Dustin Norton, A L Koch, W J Petty, S A Birken

{"title":"User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol.","authors":"T W Lycan, S N Price, K Mileham, E Stoen, J Ruiz, J A Ohar, Dustin Norton, A L Koch, W J Petty, S A Birken","doi":"10.1080/14796694.2025.2562715","DOIUrl":"10.1080/14796694.2025.2562715","url":null,"abstract":"Chronic obstructive pulmonary disease (COPD) is the most common comorbidity among patients being treated for any type of cancer with an immune checkpoint inhibitor in the medical oncology clinic. There is a critical need to measure the treatment burden of COPD and design a scalable intervention to optimize its care. Our primary aim is to determine the ideal design of a care pathway to optimize COPD in community oncology clinics. This mixed-methods study will collect data to quantify and understand the disease burdens, components of care, and barriers in the medical oncology clinic. As per user-centered design methodology, participants at design team workshops will then integrate these data into a COPD care pathway. This study will provide critical data on the impact of COPD upon patients with cancer and identify how its care can be optimized in the medical oncology clinic. These results will directly inform a novel care pathway that will be designed for scalability in the community setting. Future studies will test this pathway versus usual care in a cluster randomized controlled trial across a network of oncology clinics.Clinical Trial Registration: ClinicalTrials.gov NCT05984680.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3259-3273"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paclitaxel-based strategy as first-line therapy for advanced breast cancer: a model-based economic evaluation for China. 紫杉醇作为晚期乳腺癌一线治疗策略：中国基于模型的经济评估。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-26 DOI: 10.1080/14796694.2025.2550832

Ji-Sheng Chen, Jia Hu, Meng-Ting Li

{"title":"Paclitaxel-based strategy as first-line therapy for advanced breast cancer: a model-based economic evaluation for China.","authors":"Ji-Sheng Chen, Jia Hu, Meng-Ting Li","doi":"10.1080/14796694.2025.2550832","DOIUrl":"10.1080/14796694.2025.2550832","url":null,"abstract":"Aim: The limited number of cost-utility studies of breast cancer conducted in China makes comparisons among different paclitaxel-based strategies difficult. To provide such data, a cost-utility analysis comparing albumin-bound formulation (nab)-paclitaxel (ABPTX), paclitaxel polymer micelles (PTXPM), and paclitaxel (PTX) for advanced breast cancer was performed.Methods: Tree Age Pro 2011 software was used to simulate a Markov model to perform a health economic evaluation. Patient-related data for this study were obtained from large multicenter Phase III clinical trial studies. Quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) were considered as primary outcomes.Results: The model results showed that the 60-cycle mortality rate was 98.3% in the ABPTX group and 99.7% in the PTXPM group. Cost-utility analysis calculated that ABPTX had an increased life expectancy of 0.183 QALYs compared with patients receiving PTXPM, with an incremental cost of $4,914.747, resulting in an ICER value of $26,846.310 per QALY. When the willingness-to-pay (WTP) threshold was increased to approximately $30,000 per QALY, PTXPM had a 50% probability of being cost-effective compared with ABPTX.Conclusion: At the WTP threshold of $37,721.52/QALY in China, ABPTX is more cost-effective than PTXPM under equivalent efficacy and safety, from the Chinese healthcare perspective.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3005-3015"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review. 实体恶性肿瘤患者间质性肺病的流行病学和病因学：系统的文献综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2550928

Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane, Emily Kaiser, Ambar Khan, Pierfranco Conte

{"title":"Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.","authors":"Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane, Emily Kaiser, Ambar Khan, Pierfranco Conte","doi":"10.1080/14796694.2025.2550928","DOIUrl":"10.1080/14796694.2025.2550928","url":null,"abstract":"Background: Interstitial lung disease (ILD) can occur in patients with cancer. ILD can be caused by anti-cancer treatments (drug-induced [DI] ILD), but also by opportunistic infection, and non-drug-related etiologies. This systematic literature review (SLR) investigated the epidemiology and etiology of non-DI ILD and DI ILD management and outcomes in patients with solid cancers.Methods: Databases were searched to August 2023 using terms for ILD and solid cancers. Relevant congresses held 2021-2023 and SLR bibliographies were hand-searched. Records were screened by two independent reviewers. Inclusion criteria comprised ILD epidemiology outcomes, ILD clinical management, and survival outcomes.Results: Of 4,519 unique records screened, 55 full texts were included (six from supplementary sources) and 37 were prioritized for extraction. Studies were frequently retrospective cohort studies in Japan (n = 21). Patients mostly had lung cancers (n = 32) and received immune checkpoint inhibitors (n = 24). Reporting of non-DI ILD was limited and associated with radiation therapy (n = 4) or surgery (n = 1). Most studies reported DI ILD outcomes only (n = 31).Conclusion: The limited evidence of non-DI ILD indicates that prompt intervention to manage ILD until other ILD etiologies have been ruled out remains key to preventing progression of both cancer and ILD.Protocol registration http://www.crd.york.ac.uk/prospero identifier: CRD42023463573.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3063-3073"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zanubrutinib in the treatment of Waldenström Macroglobulinemia. 扎鲁替尼治疗Waldenström巨球蛋白血症。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-11 DOI: 10.1080/14796694.2025.2558351

Elizabeth Goodall, Stephen Opat

{"title":"Zanubrutinib in the treatment of Waldenström Macroglobulinemia.","authors":"Elizabeth Goodall, Stephen Opat","doi":"10.1080/14796694.2025.2558351","DOIUrl":"10.1080/14796694.2025.2558351","url":null,"abstract":"Waldenström Macroglobulinemia (WM) is an uncommon malignancy of IgM-secreting lymphoplasmacytic cells. The spectrum of acquired somatic mutations is heterogeneous, with MYD88 mutations occurring in more than 90%. Recurrent mutations in CXCR4, KMT2D, ARID1A, TERT, and TP53 are also detected, with some of these impacting prognosis or treatment response. The recognition of B-cell receptor (BCR) signalling in B-cell neoplasm pathophysiology led to the clinical development of the first-in-class Bruton tyrosine kinase inhibitor (BTKi) ibrutinib. Despite efficacy, off-target inhibition of TEC, EGFR, CSK and other kinases impact its safety and tolerability. The second-generation BTKi, zanubrutinib and acalabrutinib, are better tolerated with lower rates of discontinuation. Zanubrutinib is more selective for BTK than other structurally related kinases. While there have not been any studies directly comparing acalabrutinib to zanubrutinib, the efficacy of zanubrutinib was superior to ibrutinib in WM patients with MYD88 wild type, CXCR4 or TP53 mutations. However, patients with CXCR4 and TP53 mutations receiving BTKi still fare worse than those without, highlighting the need for other therapeutic strategies. Herein, we review the clinical development of zanubrutinib in WM including the impact of genetic subtypes and advise on the management of adverse events and drug resistance.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3151-3158"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation. PYNNACLE II期临床试验方案：rezatapopt （PC14586）单药治疗TP53 Y220C突变的晚期或转移性实体瘤。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-11 DOI: 10.1080/14796694.2025.2557176

Alison M Schram, Marc Fellous, Kim LeDuke, Anita Schmid, Ecaterina E Dumbrava

引用次数: 0

A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy. TROPHY-U-01研究（队列2）的简单语言总结：转移性尿路上皮癌患者不能接受顺铂化疗，免疫治疗后使用sacituzumab govitecan。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2548757

Petros Grivas, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar, Arash Rezazadeh Kalebasty, Saby George, Phillip Palmbos, Luke Nordquist, Daniel P Petrylak, Nancy Davis, Cora N Sternberg, Neeraj Agarwal, Chandler Park, Julia Tonelli, Huafeng Zhou, Rick Bangs, Yohann Loriot

引用次数: 0

Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients. 帕博西尼治疗老年晚期/转移性乳腺癌的系统综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1080/14796694.2025.2550930

Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A Gelmon

引用次数: 0

A plain language summary of LocoMMotion - an observational study of treatments used for pretreated multiple myeloma. LocoMMotion是一项用于多发性骨髓瘤预处理治疗的观察性研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1080/14796694.2025.2557174

Michel Delforge, Eilidh Duncan, María-Victoria Mateos, Imène Haddad, Wafae Iraki, Silva Koskinen, Jozefien Buyze, Philippe Moreau, Kate Morgan, Katja Weisel

引用次数: 0

Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project. 食管癌/食管贲门癌不同分期诊断和治疗的适宜性。FICOG项目。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-09 DOI: 10.1080/14796694.2025.2551482

Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato

{"title":"Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.","authors":"Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato","doi":"10.1080/14796694.2025.2551482","DOIUrl":"10.1080/14796694.2025.2551482","url":null,"abstract":"Background: Esophageal cancer is a rare neoplasm, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. The distal third of the esophagus and the gastroesophageal junction (GEJ) are mostly involved sites. The diagnosis and therapeutic management of early, locally advanced, and metastatic disease continue to present uncertainties, as existing guidelines may not fully address all clinical questions in these areas.Methods: A group of Italian Experts produced recommendations for early, locally advanced, and metastatic disease management using the RAND/UCLA Appropriateness Method. Statements were generated by a systematic revision of the literature and voted on twice by a panel of 29 expert physicians; the second vote took place during a meeting of the panelists.Results: Several topics covered diagnosis, staging, treatment, and early, localized, and metastatic disease management. Recommendations were stated.Conclusions: Interventions considered appropriate to improve compliance and outcomes of esophageal/GEJ cancer patients were identified.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3027-3041"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study. 日本套细胞淋巴瘤患者的疾病管理情况：一项真实世界的研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-07 DOI: 10.1080/14796694.2025.2555165

Shinya Rai, Yoshinori Tanizawa, Tomoko Terasawa, Masaomi Tajimi, Ryuichi Ideue, Helen Burlison, Neil Milloy, Amber Simpson, Kaisa-Leena Taipale, Min-Hua Jen, Grace Segall, Benjamin Goebel, Amit Kiran

{"title":"Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.","authors":"Shinya Rai, Yoshinori Tanizawa, Tomoko Terasawa, Masaomi Tajimi, Ryuichi Ideue, Helen Burlison, Neil Milloy, Amber Simpson, Kaisa-Leena Taipale, Min-Hua Jen, Grace Segall, Benjamin Goebel, Amit Kiran","doi":"10.1080/14796694.2025.2555165","DOIUrl":"10.1080/14796694.2025.2555165","url":null,"abstract":"Aim: The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.Methods: We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).Results: Sixty-seven patients were included - most were male (74.6%) and diagnosed with classical MCL (76.1%), with a mean age of 69.4 years and median time since MCL diagnosis of 18.0 months. The most common initial symptom was painless swelling in the neck, armpit, stomach, or groin (72%). Overall, patients had a \"complete response\" to 1 L (32/67 [47.8%]) therapy and \"partial response\" to 2 L (24/45 [53.3%]) therapy. Side effects were less commonly reported with BTKi than with chemotherapy. The most important physician-perceived treatment goal was to \"minimize impact on patient's daily life\" or \"tumor response\" for patients receiving BTKi or chemotherapy, respectively.Conclusion: Patients' disease was generally well-managed by their physicians; however, improvements in efficacy, safety, and quality of life are still needed.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3051-3062"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0